Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paricalcitol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Paricalcitol. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-006120-20 Sponsor Protocol Number: 31-06-2011 Start Date*: 2012-03-15
    Sponsor Name:University Medical Centre Ljubljana
    Full Title: Efficacy and safety of selective vitamin D receptor activation with paricalcitol for reduction of proteinuria in kidney transplant recipients: a randomized controlled trial
    Medical condition: Proteinuria in kidney transplant recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000249-18 Sponsor Protocol Number: SENPARIC-2011-01 Start Date*: 2011-08-09
    Sponsor Name:RICARDO MOUZO MIRCO
    Full Title: ACCIÓN DEL PARICALCITOL SOBRE PARÁMETROS DE INFLAMACIÓN Y ESTRÉS OXIDATIVO EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA ESTADIO Vd PORTADORES DE CATÉTERES TUNELIZADOS PARA HEMODIÁLISIS.
    Medical condition: ENFERMEDAD RENAL CRÓNICA ESTADIO VD.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004467-13 Sponsor Protocol Number: 012255 Start Date*: 2018-10-02
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancrea...
    Medical condition: Stage IV pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-002554-30 Sponsor Protocol Number: MICROBUB-2011-01 Start Date*: 2012-06-26
    Sponsor Name:Fundación Renal Jaume Arnó
    Full Title: Effect of Paricalcitol on blood vessels: an investigation over pleotropic analogues of vitamin-D.
    Medical condition: Enfermedad Renal crónica, estadío VD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003855-38 Sponsor Protocol Number: PIERAID-2013 Start Date*: 2014-09-26
    Sponsor Name:Miguel Giovanni Uriol Rivera
    Full Title: Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiv...
    Medical condition: Anaemia of inflammation in patients with chronic kidney disease on haemodialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002610-13 Sponsor Protocol Number: M11-612 Start Date*: 2013-12-06
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hem...
    Medical condition: - Stage 5 chronic kidney disease - Secondary to hyperparathyroidism
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006380-36 Sponsor Protocol Number: APPLE Start Date*: 2008-11-27
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH...
    Medical condition: Persistent secondary hyperparathyroidism in renal transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001713-14 Sponsor Protocol Number: PROCEED Start Date*: 2011-05-18
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE ANTIPROTEINURIC EFFECT OF SELECTIVE VITAMIN D RECEPTOR ACTIVATION BY PARICALCITOL IN TYPE 2 DIABETES PATI...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002877-46 Sponsor Protocol Number: PALIFE-2011-01 Start Date*: 2011-11-21
    Sponsor Name:Fundación Renal Iñigo Álvarez de Toledo
    Full Title: Paricalcitol effect vs Albumine, inflammation and Fibrosis in Chronic proteinuric kidney disease patients (PALIFE trial) Randomized, controlled trial.
    Medical condition: Proteinuric nephropatic patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006606-16 Sponsor Protocol Number: F003MN0307_1 Start Date*: 2008-07-11
    Sponsor Name:University of Wuerzburg
    Full Title: The Effects of Paricalcitol capsules on Inflammation (CRP levels) and Calcification regulation (fetuin-A levels) in CKD stage 5D patients
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011378-14 Sponsor Protocol Number: M10-967 Start Date*: 2009-11-03
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary H...
    Medical condition: Secondary hyperparathyroidism (SHPT)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020708 Hyperparathyroidism secondary LLT
    12.0 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) NL (Completed) ES (Completed) PT (Completed) GB (Completed) SE (Completed) IT (Completed) GR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021041-42 Sponsor Protocol Number: 25051954 Start Date*: 2011-01-28
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Use of Calcimimetics vs oral Paricalcitol in Renal transplant Patients affected with Persistent Secondary Hyperparathyroidism. A pilot study
    Medical condition: Renal transplant patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006645-41 Sponsor Protocol Number: SLAZ-Heuvel Start Date*: 2008-06-13
    Sponsor Name:Sint Lucas Andreas Hospital
    Full Title: The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Medical condition: Secondary hyperparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000073-24 Sponsor Protocol Number: CTRIAL-IE-19-33 Start Date*: 2020-09-07
    Sponsor Name:Cancer Trials Ireland
    Full Title: Paricalcitol Trial: Phase II, Open label clinical trial of Paricalcitol in combination with Gemcitabine/ Nab-Paclitaxel therapy in advanced pancreatic cancer.
    Medical condition: Advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016159-23 Sponsor Protocol Number: ViRTUE-2009 Start Date*: 2011-10-18
    Sponsor Name:University Medical Center Groningen (UMCG)
    Full Title: Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study
    Medical condition: chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011255-44 Sponsor Protocol Number: 2009-278 Start Date*: 2009-08-19
    Sponsor Name:Steno Diabetes Center
    Full Title: The effect of paricalcitol versus placebo on plasma NT-proBNP in patients with type 1 diabetes mellitus and diabetic nephropathy
    Medical condition: Diabetes mellitus type 1 and diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10012638 Diabetes with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005981-37 Sponsor Protocol Number: 8. udgave; 6. september 2006 Start Date*: 2006-12-20
    Sponsor Name:Roskilde Amts Sygehus
    Full Title: Behandling af sekundær hyperparathyreoidisme hos uræmiske patienter. En sammenlignenede undersøgelse mellem virkningen af alfacalcidol og paricalcitol.
    Medical condition: Secondary hyperparathyroidism is a common feature in patients with chronic kidney disease. Reduced synthesis of active vitamin D contributes to secondary hyperparathyroidism. Therefore we primaril...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001326-25 Sponsor Protocol Number: ACA-SPAI-11-24 Start Date*: 2013-07-25
    Sponsor Name:Fundación SENEFRO
    Full Title: Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after renal transplantation.
    Medical condition: Secondary hyperparathyroidism after renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001363-31 Sponsor Protocol Number: M05-741 Start Date*: 2007-05-28
    Sponsor Name:Abbott GmbH & Co KG
    Full Title: Estudio VITAL- Estudio del activador del receptor de la vitamina D selectivo (Paricalcitol) para la reducción de la albúmina: Estudio multicéntrico de fase II, prospectivo aleatorizado, a doble cie...
    Medical condition: Nefropatía diabética Tipo 2. Type 2 diabetic nephropathy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) GR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019439-37 Sponsor Protocol Number: M10-149 Start Date*: 2010-10-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Para...
    Medical condition: Moderate to Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Sep 13 21:01:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA